Benchling Inc., a San Francisco-based maker of collaborative software for life science research, raised $200 million in Series E financing led by Sequoia Capital Global Equities. New investors including Altimeter Capital and Byers Capital also participated in the round, and were joined by previous backers including Thrive Capital, Benchmark, Menlo Ventures, Iconiq Capital, Lux Capital, Spark Capital and Lead Edge Capital.
Repertoire Immune Medicines, a Cambridge, Mass.-based startup creating novel immune therapies for cancer, immune disorders, infectious disease and other serious diseases, collected $189 million in Series B financing from Flagship Pioneering, Softbank Vision Fund 2, PSP Investments, Alaska Permanent Fund, Invus and others.
Jaguar Gene Therapy LLC, a Lake Forest, Ill.-based developer of gene therapies for patients with severe genetic diseases, closed a $139 million Series B round. Eli Lilly & Co. and Deerfield Management co-led the investment, which included additional support from ARCH Venture Partners, Goldman Sachs and Nolan Capital.
Arcellx Inc., a Gaithersburg, Md.-based biopharmaceutical company that will soon initiate clinical trials of cell therapies for the treatment of multiple myeloma and acute myelogenous leukemia, scored $115 million in Series C funding co-led by Samsara BioCapital and CAM Capital. New investors including Adage, Asymmetry, CaaS Capital, Sixty Degree, Soleus Capital, Surveyor Capital, Suvretta and Terra Magnum Capital Partners also participated in the round, along with existing backers New Enterprise Associates, Novo Holdings, SR One, Takeda Ventures, LG Tech and Clough Capital.
CeQur SA, a Swiss maker of a wearable insulin patch, completed a $115 million Series C5 financing led by Credit Suisse Entrepreneur Capital and Endeavour Vision. Existing backers Schroder & Co. Bank SA and VI Partners also contributed the the round, along with new investors including Tandem Diabetes Care Inc., Ypsomed Group, Kingdon Capital and GMS Capital.
Theseus Pharmaceuticals, a Cambridge, Mass.-based developer of targeted oncology therapeutics, landed $100 million in Series B funding. Foresite Capital led the round, with Managing Director Michael Rome joining the company’s board. Adage Capital Management, Boxer Capital, Farallon Capital Management, Longitude Capital, Nextech Ventures, Omega Funds, Pontifax Venture Capital, Rock Springs Capital, T. Rowe Price and OrbiMed also participated in the round.
Papa Inc., a Miami-based platform providing companionship and clinical care to older adults and families, landed $60 million in Series C financing led by Tiger Global Management. The company is also backed by Comcast Ventures, Canaan, Initialized Capital, Sound Ventures, Pivotal Ventures and Magnify Ventures.
Cohere Health, a Boston-based healthcare collaboration platform, picked up $36 million in Series B funding. Lead investor Polaris Partners was joined by Longitude Capital, Deerfield Management, Flare Capital Partners and Define Ventures in the round.
Transparent Health Marketplace Inc., a Wayne, Pa.-based workers’ compensation healthcare services marketplace, raised $30 million in Series C financing. Artis Ventures led the round, which included participation from Phase 2 Partners and others. Stuart Peterson, founder and managing general partner at Artis, joined the board.
ImmunoScape, a Singapore-based immune profiling platform, snagged a $14 million funding round led by Anzu Partners, University of Tokyo Edge Capital Partners and EDBI.
Legacy, a Boston-based digital fertility clinic for men, fetched $10 million in Series A funding. FirstMark Capital led the investment, with founder and Partner Rick Heitzmann joining the company’s board. Other investors in Legacy include Bain Capital Ventures, Section 32, Y Combinator, TQ Ventures and Tribe Capital.
ImpriMed Inc., whose technology predicts which anti-cancer drugs are most likely to be effective for a particular dog’s lymphoma or leukemia, closed an $8 million pre-Series A round, which included $300,000 in a government grant. HG Initiative led the investment, which included contributions from Draper Associates, Draper Dragon, BonAngels, Murex Partners, Translink Investment, Primer Sazze, FuturePlay and ES Investor.
|